GemPharmatech Co., Ltd. (SHA:688046)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Commercial Mouse Model Sales	400.24M				152.60M	-	-
Functional Efficacy Business	151.38M				32.01M	-	-
Model Customization Business	33.61M				24.17M	-	-
Custom Breeding Business	85.15M				50.06M	-	-
Agent Import and Export and Others	15.89M				1.62M	-	-
Unallocated Other Operations	-				1.47M	-	-
Biotechnology	-				-	192.72M	53.29M
Biotechnology Growth	-				-	261.64%	-
Total	686.28M				261.92M	192.72M	53.29M
Total Growth	-				35.91%	261.64%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
China	572.43M				-	-	-
Overseas	113.85M				-	2.98M	726.40K
Overseas Growth	-				-	310.63%	-
East China	-				-	108.85M	27.63M
East China Growth	-				-	293.97%	-
Central China Region	-				-	10.05M	1.96M
Central China Region Growth	-				-	413.55%	-
North China	-				-	26.03M	10.19M
North China Growth	-				-	155.45%	-
Southern China	-				-	28.42M	9.65M
Southern China Growth	-				-	194.50%	-
Northwestern Region	-				-	1.40M	403.50K
Northwestern Region Growth	-				-	246.07%	-
Southwest Region	-				-	10.82M	2.21M
Southwest Region Growth	-				-	389.63%	-
Northeast China Region	-				-	2.42M	522.40K
Northeast China Region Growth	-				-	362.98%	-
Total	686.28M				-	190.98M	53.29M
Total Growth	-				-	258.37%	-

Source: S&P Global Market Intelligence.